Gupta Anu, Inaba Satoru, Wong Oi Kwan, Fang Guowei, Liu Jingwen
Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Oncogene. 2003 Oct 23;22(48):7593-9. doi: 10.1038/sj.onc.1206880.
The abnormal expression of breast cancer-specific gene 1 (BCSG1) in malignant mammary epithelial cells is highly associated with the development and progression of breast cancer. A series of in vitro and in vivo studies performed in our laboratory and others have demonstrated that BCSG1 expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. However, currently little is known about how BCSG1 exerts its oncogenic functions. To elucidate the cellular mechanisms underlying the effects of BCSG1 in breast cancer cells, we used a yeast two-hybrid system to screen for proteins that could associate with BCSG1. Through this screening, we identified the mitotic checkpoint protein BubR1 as a novel binding partner of BCSG1. The specific association of BCSG1 with BubR1 in breast cancer cells was demonstrated by immunoprecipitation and GST pull-down assays. Intriguingly, experiments conducted in four different cell lines all showed that exogenous expressions of BCSG1 consistently reduce the cellular levels of the BubR1 protein without affecting BubR1 mRNA expression. The tendency of endogenous BCSG1 expression coinciding with lower BubR1 protein levels was also observed in seven out of eight breast cancer cell lines. We further showed that the reducing effect of BCSG1 on BubR1 protein expression could be prevented by treating BCSG1-transfected cells with MG-132, a selective 26S proteasome inhibitor, implying that the proteasome machinery may be involved in the BCSG1-induced reduction of the BubR1 protein. Accompanied with a reduction of BubR1 protein level, BCSG1 expression resulted in multinucleation of breast cancer cells upon treatment with spindle inhibitor nocodazole, indicating an impaired mitotic checkpoint. Taken together, our novel findings suggest that BCSG1 may accelerate the progression of breast cancer at least in part by compromising the mitotic checkpoint control through inactivation of BubR1.
乳腺癌特异性基因1(BCSG1)在恶性乳腺上皮细胞中的异常表达与乳腺癌的发生发展高度相关。我们实验室及其他机构进行的一系列体外和体内研究表明,BCSG1的表达显著刺激乳腺癌细胞的增殖、侵袭和转移。然而,目前对于BCSG1如何发挥其致癌功能知之甚少。为了阐明BCSG1在乳腺癌细胞中作用的细胞机制,我们使用酵母双杂交系统筛选与BCSG1相互作用的蛋白质。通过该筛选,我们鉴定出有丝分裂检查点蛋白BubR1是BCSG1的一个新的结合伙伴。免疫沉淀和GST下拉实验证明了BCSG1与BubR1在乳腺癌细胞中的特异性结合。有趣的是,在四种不同细胞系中进行的实验均表明,BCSG1的外源性表达持续降低BubR1蛋白的细胞水平,而不影响BubR1 mRNA的表达。在八株乳腺癌细胞系中的七株中也观察到内源性BCSG1表达与较低的BubR1蛋白水平一致的趋势。我们进一步表明,用选择性26S蛋白酶体抑制剂MG-132处理转染了BCSG1的细胞,可以阻止BCSG1对BubR1蛋白表达的降低作用,这意味着蛋白酶体机制可能参与了BCSG1诱导的BubR1蛋白减少。伴随着BubR1蛋白水平的降低,在用纺锤体抑制剂诺考达唑处理后,BCSG1的表达导致乳腺癌细胞多核化,表明有丝分裂检查点受损。综上所述,我们的新发现表明,BCSG1可能至少部分地通过使BubR1失活从而损害有丝分裂检查点控制来加速乳腺癌的进展。